ROSGQ (Rosetta Genomics) Other Long-Term Liabilities: $-0.00 Mil (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rosetta Genomics Other Long-Term Liabilities?

Rosetta Genomics ROSGQ Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2017.

Rosetta Genomics's other long-term liabilities for the quarter that ended in Jun. 2017 was $-0.00 Mil.

Rosetta Genomics's quarterly other long-term liabilities declined from Jun. 2016 ($0.00 Mil) to Dec. 2016 ($-0.00 Mil) but then stayed the same from Dec. 2016 ($-0.00 Mil) to Jun. 2017 ($-0.00 Mil).

Rosetta Genomics's annual other long-term liabilities declined from Dec. 2014 ($0.00 Mil) to Dec. 2015 ($0.00 Mil) and declined from Dec. 2015 ($0.00 Mil) to Dec. 2016 ($-0.00 Mil).

Rosetta Genomics Other Long-Term Liabilities Related Terms

Rosetta Genomics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Other Long-Term Liabilities Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.08 0.00 0.00 -0.00

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 -0.00 -0.00

Rosetta Genomics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $-0.00 Mil mean?
Rosetta Genomics (ROSGQ) has a Other Long-Term Liabilities of $-0.00 Mil as of Jun. 2017. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Other Long-Term Liabilities too high?
Rosetta Genomics' current Other Long-Term Liabilities is $-0.00 Mil.
How does Rosetta Genomics' Other Long-Term Liabilities compare to TEAR and IDTA?
Rosetta Genomics' Other Long-Term Liabilities of $-0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Medical Diagnostics & Research company?
A good Other Long-Term Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current Other Long-Term Liabilities is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Other Long-Term Liabilities of $-0.00 Mil. The current Other Long-Term Liabilities is $-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Other Long-Term Liabilities is $-0.00 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.